Navigation Links
QLT reports initial proof of concept data for punctal plug delivery technology
Date:5/12/2008

oday are an early indication that QLT's drug elution technology has the potential to provide a meaningful therapeutic benefit. To generate proof of concept data for the Company's proprietary punctal plug drug delivery system, QLT is currently enrolling patients in the CORE study, a Phase 2, randomized, double blind trial to assess the safety and efficacy of its latanoprost punctal plug delivery system for the treatment of glaucoma and ocular hypertension at three different doses (low, medium, high). The medium dose of latanoprost in the CORE Study was used in the trial that is being reported today.

About QLT

QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies. Our research and development efforts are focused on pharmaceutical products in the fields of ophthalmology and dermatology. In addition, we utilize three unique technology platforms, photodynamic therapy, Atrigel(R) and punctal plugs with drugs, to create products such as Visudyne(R) and Eligard(R) and future product opportunities. For more information, visit our web site at http://www.qltinc.com.

QLT Plug Delivery, Inc. is a wholly-owned subsidiary of QLT Inc.

Atrigel is a registered trademark of QLT USA, Inc.

Visudyne is a registered trademark of Novartis AG.

Eligard is a registered trademark of Sanofi-aventis.

QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol "QLTI" and on The Toronto Stock Exchange under the trading symbol "QLT."

Certain statements contained in this press release, which are not historical facts, are "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995 and constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements include, but are not limited to: our beliefs re
'/>"/>

SOURCE QLT Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Neurobiological Technologies Reports Third Quarter Financial Results
2. Bionovo Reports First Quarter 2008 Financial Results
3. WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders Meeting
4. Cardium Reports on First Quarter 2008 Highlights and Financial Results
5. Novavax Reports First Quarter 2008 Financial Results
6. Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance
7. Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results
8. Pharmos Corporation Reports 2008 First Quarter Results
9. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
10. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
11. Favrille Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/3/2008)...Symbol: MS, EDMONTON, Oct. 3 /PRNewswire-FirstCal...loper in the treatment of multiple sclerosis (MS),...Monitoring Board (DSMB) for the,Company,s U.S. piv...8298),in patients with secondary progressive MS ha... the trial continue as per the protocol., This wa...
(Date:10/3/2008)...or Ap3ana, CTI,s ,personalized medicine, venture, ...erapeutics, Inc. (CTI),(Nasdaq: CTIC ) announced ...t recently President and COO of a Tyr Pharma and f...mics Institute of the Novartis Research,Foundation... Bresso, Italy,CTI Europe currently conducts the ...
(Date:10/2/2008)...2 /- Helix BioPharma,Corp. ... its private,placement announced on September 30, ...ss proceeds totaling CDN$11,424,000., Each unit c...mmon share,purchase warrant, with each whole commo...urchase, subject to adjustment, one common share a...
(Date:10/2/2008)...Provides Business Update to Investors, WILMINGTON...today at an,investor conference, DuPont Vice Presi...ny,s plans to bring its two advanced biofuels prog... technical progress toward the,commercialization o...stocks,economically into biofuels., "Biobutanol a...
Breaking Biology Technology:BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 2Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 3Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 4Helix Biopharma Closes $11.4 Million Private Placement 2DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 2DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 3
... Businesses could lose important trademark right...ents of the U.S. Patent and Trademark Office and t...ed by an international case of earlier this year. ...smetische Erzeugnisse mbH , the Trademark Trial an...nsion of time to oppose an international, or Madri...
... As Im writing this column, I was reminded by an...John Lennons birthday. , ,As he was born on Oct. 9...still alive. He was shot outside his apartment bui...ticle gave a fascinating perspective on probably t...this statement is going to provoke some comment bu...
... Madison , Wis. - Three UW-Madison scientists...m cells to turn into pancreatic islet cells, the ...nced last week. The procedure has the potential to...ble for transplantation into diabetic patients. , ...ahan, and Nathan R. Treff, have applied for a pate...
... At DEMO 2004 I hosted a panel The Rise of the B...om, blogging was pass; of course everyone was blog... blogging with a blank stare; what, after all, was...singly apparent as blogging moves from the journal...nal of corporate America. But 18 months since that...
Other Biology Technology:Ruling enforces international trademark electronic filing requirements 2Ruling enforces international trademark electronic filing requirements 3Midwest biotech stocks drop like a rock during the third quarter 2Midwest biotech stocks drop like a rock during the third quarter 3Blogging moves to corporate America 2Blogging moves to corporate America 3
(Date:10/5/2008)...n the Journal of Cell Biology how the altered be... in tumor cells., On 2D surfaces, cells may migra...ins, which link the cell to the extracellular matr...but exactly how has been unclear. Recent work has ...om movement, while an integrin called avb3 has bee...
(Date:10/5/2008)...8 Scientists report online this week in Nature ...t immune cells to a gene associated with Crohn,s d...valent inflammatory bowel disorder. , The link t... University School of Medicine in St. Louis becaus...d by misdirected immune responses in the intestine...
(Date:10/3/2008)...(Oct. 2, 2008)Researchers from Harvard Medical Sch...iscovered how beetles and bacteria form a symbioti...results in the destruction of pine forests. In add...at drives this whole phenomenon. , The context ...y arc that includes some of the most unlikely char...
(Date:10/3/2008)...life cycle of Atlantic bluefin tuna shows, for the... bluefin mix substantially as juveniles, but retur...arch findings have critical implications for how b...tic. , Research appearing in the journal Scien...of Texas A&M University and Dr. David Secor of the...
Breaking Biology News(10 mins):Form of Crohn's disease traced to disabled gut cells 2Cross kingdom conflicts on a beetle's back 2Cross kingdom conflicts on a beetle's back 3Scientists Find new migratory patterns for Mediterranean and Western Atlantic bluefin tuna 2Palatin Technologies Inc Reports Fourth Quarter and Fiscal Year End 2007 Results 3B Teleconference and Webcast to be held on September 18 2007 582 1Palatin Technologies Inc Reports Fourth Quarter and Fiscal Year End 2007 Results 3B Teleconference and Webcast to be held on September 18 2007 582 2Palatin Technologies Inc Reports Fourth Quarter and Fiscal Year End 2007 Results 3B Teleconference and Webcast to be held on September 18 2007 582 3Palatin Technologies Inc Reports Fourth Quarter and Fiscal Year End 2007 Results 3B Teleconference and Webcast to be held on September 18 2007 582 4Palatin Technologies Inc Reports Fourth Quarter and Fiscal Year End 2007 Results 3B Teleconference and Webcast to be held on September 18 2007 582 5Palatin Technologies Inc Reports Fourth Quarter and Fiscal Year End 2007 Results 3B Teleconference and Webcast to be held on September 18 2007 582 6Palatin Technologies Inc Reports Fourth Quarter and Fiscal Year End 2007 Results 3B Teleconference and Webcast to be held on September 18 2007 582 7Palatin Technologies Inc Reports Fourth Quarter and Fiscal Year End 2007 Results 3B Teleconference and Webcast to be held on September 18 2007 582 8Updated GOLD report presents new understandings in diagnosis treatment and prevention of COPD 1252 1Updated GOLD report presents new understandings in diagnosis treatment and prevention of COPD 1252 2USA TODAY Concludes Spirit of the USA Charity Program as Part of Newspapers 25th Anniversary Celebration 1249 1USA TODAY Concludes Spirit of the USA Charity Program as Part of Newspapers 25th Anniversary Celebration 1249 2USA TODAY Concludes Spirit of the USA Charity Program as Part of Newspapers 25th Anniversary Celebration 1249 3Researchers discover correlation between GERD and obesity in females 1245 1
...at the University of California, San Diego has sho...e to sequence DNA as it passes through tiny pores....dicine closer to reality. , The paper, published i...cribes a method to sequence a human genome in a ma...ing the electrical perturbations generated by a si...
...have determined that night blindness is a new clin...rd Hughes Medical Institute (HHMI) international r...aveto of the Institute for Genetic Engineering and...ncil, National Council of Scientific Research and ...system of individuals with the tropical disease ca...
...d a method to engineer blood vessels within the ti...s have resulted in significant improvement in hear... Artificial Organs. , With heart disorders affec...easing mortality rates, there has been a need to d... challenges in the field of tissue engineering is ...
...resurrecting ancient genes, scientists have for th... of an apparently "irreducibly complex" molecular ...sistant professor of biology at the University of ...gy, and will be published in the April 7 issue of ...olution of complex molecular systems ?those in whi...
Other Biology News:Nanopore method could revolutionize genome sequencing 2Nanopore method could revolutionize genome sequencing 3A case of mistaken molecular identity 2A case of mistaken molecular identity 3Evolution of 'irreducible complexity' explained 2
Tissue-Stat ( Tissue Adherent for Mounting Formalin-Fixed and Frozen Tissue Sections.)
AM100 is an aqueous-based, permanent mounting media designed for use with alkaline phosphatase and immunoperoxidase stained tissue sections.
...formulated for covering tissue sections and cell p...omogens producing alcohol soluble OR alcohol insol...ith chromogens such as Fast Red or AEC that requir..., such as DAB. No heating is required prior to use...
Rabbit polyclonal to JAK2 (phospho Y1007) ( Abpromise for all tested applications). Antigen: Synthesized phosphopeptide derived from human JAK2 around the phosphorylation site of tyrosine 1007 (
Biology Products: